The Translational and Clinical Research (TACR) Program was established in early 2016 as a forward-looking, proactive response to an ongoing shift in translational and clinical cancer research away from disease-centric paradigms, and toward cross-disease site innovation and development. TACR represents the interface between basic science Programs and the clinic-based, disease-specific research groups and is designed to expedite the translation of innovative clinical approaches developed by University of Michigan Comprehensive Cancer Center (UMCCC) researchers to the clinic. The program is comprised of 69 members from 24 different departments representing 6 different schools and colleges. In 2016, TACR members had a total of $28.8M in annual (DC) cancer grant funding, of which $7M (24.3%) is from NCI, $2.7M (9.4%) is from other NIH, and $12.6M (43.7%), is total peer-reviewed. In addition, TACR members are supported by grants from drug and device companies with total funding of $14.5M (50.4%). Investigators are involved in intra- and inter-programmatic interactions and actively collaborate with researchers in the other UMCCC programs within most of the Basic Science and Cancer Control and Population Sciences Programs. Members have a total of 1423 publications, of which 31.1% are intra-programmatic and 50.6% are inter-programmatic. The TACR program has three main Specific Aims: I) use state-of-the-art genomic approaches to make discoveries that advance patient care; II) Advance novel UMCCC concepts and agents into human trials to expedite the translation of laboratory discoveries to the clinic; and III) Develop and test new predictive biomarker and disease monitoring strategies for improving patient care.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Michigan Ann Arbor
Ann Arbor
United States
Zip Code
Mendiratta-Lala, Mishal; Gu, Everett; Owen, Dawn et al. (2018) Imaging Findings Within the First 12 Months of Hepatocellular Carcinoma Treated With Stereotactic Body Radiation Therapy. Int J Radiat Oncol Biol Phys 102:1063-1069
Cilliers, Cornelius; Menezes, Bruna; Nessler, Ian et al. (2018) Improved Tumor Penetration and Single-Cell Targeting of Antibody-Drug Conjugates Increases Anticancer Efficacy and Host Survival. Cancer Res 78:758-768
Lorenz, Daniel A; Vander Roest, Steve; Larsen, Martha J et al. (2018) Development and Implementation of an HTS-Compatible Assay for the Discovery of Selective Small-Molecule Ligands for Pre-microRNAs. SLAS Discov 23:47-54
Zhou, Bing; Hu, Jiantao; Xu, Fuming et al. (2018) Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression. J Med Chem 61:462-481
Cho, Chun-Seok; Park, Hwan-Woo; Ho, Allison et al. (2018) Lipotoxicity induces hepatic protein inclusions through TANK binding kinase 1-mediated p62/sequestosome 1 phosphorylation. Hepatology 68:1331-1346
Chockley, Peter J; Chen, Jun; Chen, Guoan et al. (2018) Epithelial-mesenchymal transition leads to NK cell-mediated metastasis-specific immunosurveillance in lung cancer. J Clin Invest 128:1384-1396
Hertz, Daniel L; Kidwell, Kelley M; Vangipuram, Kiran et al. (2018) Paclitaxel Plasma Concentration after the First Infusion Predicts Treatment-Limiting Peripheral Neuropathy. Clin Cancer Res 24:3602-3610
Parsels, Leslie A; Karnak, David; Parsels, Joshua D et al. (2018) PARP1 Trapping and DNA Replication Stress Enhance Radiosensitization with Combined WEE1 and PARP Inhibitors. Mol Cancer Res 16:222-232
Menghrajani, Kamal; Boonstra, Philip S; Mercer, Jessica A et al. (2018) Predictive models for splenic response to JAK-inhibitor therapy in patients with myelofibrosis. Leuk Lymphoma :1-7
Xiong, Xiufang; Liu, Xia; Li, Haomin et al. (2018) Ribosomal protein S27-like regulates autophagy via the ?-TrCP-DEPTOR-mTORC1 axis. Cell Death Dis 9:1131

Showing the most recent 10 out of 1493 publications